StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Monday. The firm set a “hold” rating on the stock.

DBVT has been the topic of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright boosted their price objective on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $3.57 on Monday. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $10.70. The company has a fifty day moving average of $3.46 and a 200-day moving average of $3.99. The stock has a market capitalization of $73.43 million, a price-to-earnings ratio of -0.79 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.